

PHARMION CORP  
Form 8-K  
February 14, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported) February 13, 2008  
Pharmion Corporation  
(Exact name of registrant as specified in its charter)**

**Delaware**

**000-50447**

**84-1521333**

(State or other jurisdiction  
of incorporation)

(Commission File  
Number)

(IRS Employer  
Identification No.)

**2525 28<sup>th</sup> Street, Boulder,  
Colorado**

**80301**

(Address of principal executive  
offices)

(Zip Code)

Registrant's telephone number, including area code **720-564-9100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On February 13, 2008, the Compensation Committee of the Board of Directors of Pharmion Corporation (the Company ) met and determined annual incentive bonus awards for 2007 to be paid to the Company s chief executive officer, chief financial officer and the other named executive officers and adjustments to those named executive officers annual base salary effective March 1, 2008.

At the beginning of each year, the Compensation Committee looks back to the immediately preceding year and evaluates the performance of the named executive officers against annual bonus targets both on a corporate and individual level that were established at the commencement of that year. Bonuses are awarded based upon this determination. In addition, the Compensation Committee annually reviews compensation data to make determinations regarding the authorized range of salary increases within the Company, generally, and specifically evaluates and establishes the salary levels for the named executive officers.

Set forth below are the 2007 annual incentive bonus awards and the 2008 base salaries for each of the Company s named executive officers as determined by the Compensation Committee:

Name	2007 Incentive Bonus	2008 Base Salary
Patrick J. Mahaffy, President, Chief Executive Officer and Director	\$570,000	\$595,000
Michael Cosgrave, Chief Commercial Officer *	\$355,520	\$460,000
Andrew Allen, Executive Vice President and Chief Medical Officer	\$292,000	\$380,000
Gillian Ivers-Read, Executive Vice President - Development Operations	\$280,000	\$365,000
Erle T. Mast, Executive Vice President and Chief Financial Officer	\$280,000	\$365,000

\* Actual 2008 base salary paid will be £235,481 and actual 2007 incentive bonus paid will be £181,996, converted into U.S. dollars at an exchange rate of 1.953.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PHARMION CORPORATION**

Date: February 14, 2008

By: /s/ Steven Dupont

Name: Steven Dupont

Title: Executive Vice President and General Counsel